Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024.Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. Bourla's remarks on the company's first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations t ...